PEPG

PepGen Inc. (PEPG) 2024 Annual Report (10-K) Summary

Business Context and Reporting Period

Company: PepGen Inc.
Reporting Period: Fiscal year ended December 31, 2024.
Business Model: Clinical-stage biotechnology company developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases using its proprietary Enhanced Delivery Oligonucleotide (EDO) platform.
Key Programs:

• PGN-EDO51: Targeting Duchenne Muscular Dystrophy (DMD) via exon 51 skipping. Currently in Phase 2 trials (CONNECT1 in Canada; CONNECT2 in the U.K.).
• PGN-EDODM1: Targeting Myotonic Dystrophy Type 1 (DM1). Currently in Phase 1 (FREEDOM) and Phase 2 (FREEDOM2) trials.

Key Financial Metrics

Note: The company has no debt and no products approved for sale. Liquidity is supported by cash reserves and recent equity financing.

Material Changes vs. Prior Period

• Increased Net Loss: Net loss increased by approximately $11.4 million (14.6%) year-over-year, driven by higher operating expenses.
• R&D Expense Growth: R&D expenses rose by $8.4 million, primarily due to the advancement of clinical trials for PGN-EDO51 and PGN-EDODM1, increased personnel costs, and higher stock-based compensation.
• Financing Activity: In February 2024, the company raised $86.3 million in net proceeds through an At-the-Market (ATM) offering and a Follow-on Offering, significantly bolstering cash reserves compared to the prior year.
• Corporate Structure: The U.K. subsidiary, PepGen Limited, was dissolved in December 2024, resulting in a one-time tax benefit of $0.7 million.

Guidance, Outlook, and Risks

Outlook: Management believes current cash resources ($120.2 million) are sufficient to fund operations for at least 12 months from the filing date. The company expects expenses to increase in 2025 as it continues Phase 2 trials.

Regulatory Status & Unusual Items:

• FDA Clinical Hold: In December 2024, the FDA issued a clinical hold on the initiation of the CONNECT2 Phase 2 trial for PGN-EDO51 in the U.S. The company is working to resolve questions regarding supportive data for planned dosing levels.
• Health Canada Inquiry: Health Canada has requested additional information to address safety concerns before allowing further dose escalation or enrollment in the CONNECT1 trial, though current dosing at 5 and 10 mg/kg may continue.
• Clinical Data: Early data from PGN-EDO51 (CONNECT1) showed favorable safety and promising exon skipping. PGN-EDODM1 (FREEDOM) showed robust splicing correction in early cohorts.

Key Risks:

• Failure to resolve regulatory holds (FDA/Health Canada) could delay development timelines.
• Need for substantial additional funding to sustain operations beyond the next 12 months.
• High failure rate inherent in clinical-stage biotechnology; no products approved for sale.
• Competition from established therapies and other oligonucleotide/gene therapy developers.

Investor Verification Checklist

• Regulatory Resolution: Monitor the status of the FDA clinical hold on the CONNECT2 trial and Health Canada's response to safety inquiries regarding CONNECT1.
• Cash Burn Rate: Verify the sustainability of the $120.2 million cash position against the projected increase in R&D expenses for 2025.
• Clinical Milestones: Track upcoming data readouts: PGN-EDO51 10 mg/kg cohort data (expected Q3 2025) and PGN-EDODM1 15 mg/kg cohort data (expected H2 2025).
• Capital Markets: Assess the company's ability to raise additional capital if clinical timelines extend or if regulatory hurdles require more extensive studies than planned.
• Intellectual Property: Review the status of the OUI/MRC license agreement and the expiration dates of key patents (ranging from 2035 to 2045).